<div dir="ltr">I read the articles with great interest, even though the patients appeared to be travelers who got CL and returned to France and England.<div><br></div><div>KP</div></div><div class="gmail_extra"><br><div class="gmail_quote">On Fri, Feb 19, 2016 at 12:46 PM, Carlos Costa <span dir="ltr"><<a href="mailto:chncosta@gmail.com" target="_blank">chncosta@gmail.com</a>></span> wrote:<br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex">Dear Bartira,<div><br></div><div>I fully agree with Pierre.</div><div><br></div><div>Cheers,</div><div><br></div><div>Carlos.<span></span><br><br>Em sexta-feira, 19 de fevereiro de 2016, Pierre Buffet <<a href="mailto:pabuffet@gmail.com" target="_blank">pabuffet@gmail.com</a>> escreveu:<br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex"><div dir="ltr"><div class="gmail_default" style="font-size:small">Dear Bartira,</div><div class="gmail_default" style="font-size:small"><br></div><div class="gmail_default" style="font-size:small">please find attached 2 references on this topic that bring contrasted responses to your question (but "selection" criteria were different).</div><div class="gmail_default" style="font-size:small"><br></div><div class="gmail_default" style="font-size:small">In our experience about one third of CL patients treated with antimony and liposomal amphotericin B interrupt their treatment due to systemic side effects of variable severity. Interruption depends on the side effect but also on the indication. I would spend more energy and accept a higher level of risk to treat an immunocompromised patient with visceral leishmaniasis unresponsive to amphotericin B than an immunocompetent patient with localized CL (most of whom should in my opinion be treated locally).</div><div class="gmail_default" style="font-size:small"><br></div><div class="gmail_default" style="font-size:small">Hope this is helpful.</div><div class="gmail_default" style="font-size:small"><br></div><div class="gmail_default" style="font-size:small">All the best</div><div class="gmail_default" style="font-size:small"><br></div><div class="gmail_default" style="font-size:small">Pierre</div><div class="gmail_default" style="font-size:small"><br></div></div><div class="gmail_extra"><br><div class="gmail_quote">2016-02-18 20:35 GMT+01:00 Bartira Rossi Bergmann <span dir="ltr"><<a>bartira@biof.ufrj.br</a>></span>:<br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex">Dear colleagues,<br>
<br>
Does anybody have an idea of the percentage of patients that do not complete the whole series of injections (overall available injectable drugs) against cutaneous leishmaniasis - locally or worldwide - due to adverse side effects?<br>
<br>
Thanks a lot!<br>
<br>
Bartira<br>
<br>
<br>
<br>
<br>
-- <br>
Bartira Rossi Bergmann<br>
Professora Associada<br>
Instituto de Biofísica Carlos Chagas Filho<br>
Universidade Federal do Rio de Janeiro - Brasil<br>
tel: <a href="tel:%2B55%20%2821%29%202260-6963" value="+552122606963" target="_blank">+55 (21) 2260-6963</a><br>
_______________________________________________<br>
Leish-l mailing list<br>
<a>Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" rel="noreferrer" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
--<br>
This email was sent by <a href="http://icb.usp.br" rel="noreferrer" target="_blank">icb.usp.br</a><br>
</blockquote></div><br><br clear="all"><div><br></div>-- <br><div><div dir="ltr"><div><div dir="ltr"><div dir="ltr"><div dir="ltr"><div dir="ltr"><div>Pr. Pierre Buffet, MD, PhD</div><div>Faculté de Médecine Université Paris Descartes</div><div>Institut National de la Transfusion Sanguine</div><div>6 rue Cabanel, 75015 Paris</div>
<div><span style="font-size:12.8000001907349px">Paris, France</span><br></div>
<div>Téléphone: <a href="tel:%2B33%20%280%296%2026%2016%2068%2011" value="+33626166811" target="_blank">+33 (0)6 26 16 68 11</a></div>
<div><a>pabuffet@gmail.com</a></div><div><br></div>
<div><br></div></div></div></div></div></div></div></div>
</div>
<br><br>--<br>
<i> This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a> </i>
</blockquote></div><br><br>-- <br><div dir="ltr"><div style="text-align:left"><span style="font-family:verdana,sans-serif">Carlos H. N. Costa, MD, DSc.</span></div><div style="text-align:left"><span style="font-family:verdana,sans-serif">Coordenador</span></div><div style="text-align:left"><span style="font-family:verdana,sans-serif">Laboratório de Leishmanioses - LabLeish</span></div><div style="text-align:left"><span style="font-family:verdana,sans-serif">Universidade Federal do Piauí</span><br></div><div><div style="text-align:left"><span style="font-family:verdana,sans-serif">Instituto de Doenças Tropicais Natan Portella</span></div><div style="text-align:left"><font face="verdana, sans-serif">Rua Artur de Vasconcelos 151-Sul</font></div><div><div style="text-align:left"><span style="font-family:verdana,sans-serif">64001-450 Teresina-PI</span></div><font face="verdana, sans-serif"><div style="text-align:left">Brazil</div><div style="text-align:left">Telephones: <a href="tel:%2B55%2086%203222-4377" value="+558632224377" target="_blank">+55 86 3222-4377</a> (W), <div style="text-align:center;display:inline!important"><div style="text-align:center;display:inline!important"><a href="tel:%2B55%2086%203221-3062" value="+558632213062" target="_blank">+55 86 3221-3062</a> (W), </div></div><div style="text-align:center;display:inline!important"><a href="tel:%2B55%2086%203237-1075" value="+558632371075" target="_blank">+55 86 3237-1075</a> (R). </div></div><div style="text-align:left"><br></div><div style="text-align:left"><br></div><span style="font-size:x-small"><div style="text-align:left">Aviso: As informações contidas nesta mensagem são CONFIDENCIAIS, protegidas pelo sigilo legal, por direitos autorais e destinadas exclusivamente à pessoa ou organização para a qual a mensagem foi destinada.</div><div style="text-align:left">Warning: This message is meant only for the intended recipient of the transmission. It is forbidden any unauthorized use, alteration, reproduction and distribution. If you are not the correct recipient, please notify us immediately by return e-mail and delete this message from your system.</div></span></font></div></div></div><br>
<br><br>--<br>
<i> This email was sent by <a href="http://icb.usp.br" target="_blank">icb.usp.br</a> </i>
<br>_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" rel="noreferrer" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br>
--<br>
This email was sent by <a href="http://icb.usp.br" rel="noreferrer" target="_blank">icb.usp.br</a><br>
<br></blockquote></div><br></div>